ng/patch for S-methadone. The ratio between R-and Smethadone was in the range of 0.72 to 2.66 and was higher than 1.00 in 15 samples. No correlation between the doses of methadone administered and the concentrations of methadone in sweat was observed.
Although urine drug testing is reliable, economical, widely used, and tightly regulated, interest in the use of alternate biologic specimens has increased. Until recently, the analysis of drugs in sweat was rarely performed because it is extremely difficult to collect the specimen, and therefore, to estimate sweat volume and evaluate drug concentrations. Significant advances have been made by Pharmchem Laboratories (Menlo Park, CA, U.S.A.) in marketing a sweat patch under the tradename PharmChek.
The sweat patch acts as a specimen container for nonvolatile and liquid components of sweat, including drugs. Sweat, approximately a minimum of 300µl per day of insensible perspiration, is collected on a special absorbent pad of approximately 14 cm 2 , which is located in the center of the patch. Over a period of several days, sweat saturates the pad, and drugs that are present are retained.
Several papers document the usefulness of the sweat patch in the monitoring of drug exposure. First, controlled studies were investigated to validate this new technology, involving cocaine (1,2), opiates (2, 3) , barbiturates (3), benzodiazepines (4), methamphetamine (5), theophylline (6) , and N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine or MBDB (7) . More recently, the applications in the treatment and monitoring of substance abusers in detoxification centers were described (6, 8, 9) . All the authors concluded that sweat analysis may be a useful adjunct to conventional drug testing in urine.
Methadone is used in detoxification and maintenance programs for the management of physical dependence of narcotics. The high oral bioavailability of methadone favors its use by the oral route (10) . However, studies in maintenance patients have indicated that a potential of accumulation exists because of a wide interindividual range of the terminal half-life of the drug (11), leading to dose adjustment on the basis of individual pharmacokinetic parameters.
Methadone contains a chiral carbon atom, and therefore, exists in two stereoisomeric forms. (R)-(-) methadone, also named levomethadone, has been estimated to be 25 to 50 times more potent than (S)-(+) methadone in clinical studies (12) . Although the enantiomers show different pharmacodynamic and pharmacokinetic parameters, it is usually the racemate that is administered.
Stereoselective determination of both enantiomers of methadone has been described for blood (13) (14) (15) (16) , urine (17) , and hair (18) . Results indicated a predominance of the Renantiomer in urine and hair, whereas they were rather suggestive of a predominance of the S-enantiomer in blood, with large interindividual differences. The predominance of the S-enantiomer in serum was explained by the shorter elimination half-life and the lower bioavailability of the Renantiomer.
As drugs are incorporated in hair by two mechanisms, i.e., the blood stream and the mixture sweat/sebum that bathe the hair (19) , it is of major interest to determine which enantiomer predominates in sweat to better understand the mechanisms by which drugs are present in hair.
In this study, the following aspects were under investigation: evaluation of methadone excretion in sweat, evaluation of the enantiomers ratio, and evaluation of the correlation between the administered dose and the concentration in sweat.
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MATERIALS AND METHODS
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Chemicals and Equipment
Methanol and isopropanol were high-performance liquid chromatography grade(Merck, Darmstadt, Germany). All other chemicals were analytical grade and supplied by Merck. 
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Specimens
Sweat was collected from 20 white subjects (13 males, 7 females) by using the PharmChek sweat patch. Patches were worn by heroin addicts who were taking part in a methadone substitution program in Mulhouse (France). Subjects were in the program for several months before they were included in this study. Subjects were orally administered, under controlled conditions, racemic methadone hydrochloride in a 15-ml syrup (Laboratories Mayoly Spindler, Chatou, France) once each morning. Methadone doses ranged from 80 to 100 mg. The sweat patch was applied 10 minutes before the methadone administration to the outer portion of the upper back. The selected skin site for patch placement was gently cleaned with a 70% isopropanol swab before application. The patch was removed 72 hours later, just before a new methadone administration (each subject received three doses of methadone), by pulling an edge of the adhesive backing, taking care not to touch the absorbent pad. After removal of the patch, the pad was stored in sealed plastic tubes at -20°C. Each pad was stored in a separate tube.
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Analysis of the Sweat Patches 
Liquid Chromatography-Mass Spectrometry A 2-µl portion of the sample was injected into the liquid chromatography-mass spectrometry system. A 20-ml dualsyringe high-performance liquid chromatography pump (model 140B; Applied Biosystems, Forster City, Canada) was used to deliver the pulse-free, low flow rates required by the ionspray interface. Samples were manually injected using a 100-µl gastight syringe (Hamilton model 1710) and a Rheodyne model 8125 low-dispersion valve equipped with a homemade 2.0 µl PEEK loop (0.127 mm ID).
The high-performance liquid chromatography separations were performed on a 5-µm CHIRAL-AGP Chromtech column (100 by 4.0 mm ID), operated at ambient temperature and protected by a 5-µm alpha 1-AGP (Chromtech) guard cartridge (10 × 3.0 mm ID). Each 18.5-minute chromatographic run was carried out with a binary mobile phase of isopropanol/2 mM NH 4 COOH, pH 5.8 buffer, using the following gradient: isopropanol at 8% hold for 8 minutes, up to 20% at 9 minutes then isocratic to 18 minutes; down to 8% at 18.5 minutes. The flow rate was 500 µl/minute (operating pressure in the range 4.7 to 8.1 MPa) with a postcolumn split (a zero-dead volume tee with two outlets of unequal length) of 1:9, to reduce at 50 µl/minute the flow rate infused into the ionspray. An equilibration time of 5 minutes at 8% isopropanol was allowed between two successive runs. Before use, the components of the mobile phase were degassed and filtered through 0.45-µm filters (Durapore GVWP 047; Millipore, Bedford, MA, U.S.A.) with a Pyrex filter holder (Millipore). At the end of each chromatographic session, the column was unplugged from the detector, then thoroughly rinsed with isopropanol/deionized water (25:75 for 3 hours) at a flow rate of 500µl/minute.
Mass spectrometry detection was carried out using an API-100 quadrupole instrument (Perkin-Elmer Sciex, Foster City, Canada). Nitrogen was used as the nebulizing gas (flow rate, 1.16 l/minute). The instrument was operated in the positive ionization mode with a voltage of +4.5 kV applied to the sprayer during all experiments. To prevent solvent vapors and contaminants from entering the vacuum chamber, the area in front of the orifice was continuously flushed with a "curtain gas" (N 2 , 40 psi) at a flow rate of 1.08 l/minute during all experiments and 0.14 l/minute when the instrument was set in overnight standby.
The system was tuned weekly by using a continuous infusion at 5µl/minute of the standard mixture of high molecular weight propylene glycols (monitoring the ions at m/z 59, 175, 616, 907, 1255, 1545, 1836, and 2010) for mass calibration, lens optimization, and peak width adjustments. Mass spectrometry data were collected as either total ion chromatograms by monitoring the signal over a large, continuous mass range or in the selected ion monitoring mode by focusing the detector on a sole mass, or on a list of masses, respectively.
The following ions were selected for identification and quantification ( Fig. 1) : m/z 265 and 310, and 268 and 313, for methadone and methadone-d 3 , respectively. 
RESULTS AND DISCUSSION
Under the chromatographic conditions used, there was no interference with the drug or the internal standard by any extractable endogenous material in sweat. Control (blank) sweat patches were also free of interference. The chromatograms obtained showed a good separation. Figure 2 presents the chromatogram obtained after extraction of a patch from a subject under methadone treatment. Analytical parameters are presented Table 1 . There was no noticeable difference between the R-and S-enantiomer. Standard curve was constructed by addition of methadone (10, 50, 100, 200, 500, or 1000 ng in methanol) and methadone-d 3 (200 ng) to a drug-free absorbent pad. The Table 1 assay was linear in the range tested. The limit of detection for both enantiomers was 2.0 ng/patch with a minimum signal-to-noise ratio of 1:3. The extraction recovery was [almost equal to]86% and within-run coefficient of variation was<13%. The precision was assessed by passing nine drugfree absorbent pads that were spiked with 100 ng of methadone through the entire procedure in 1 analysis day.
Subjects wore the patch with minimal discomfort for 3 days. It was possible for each subject to continue with the usual hygiene practices. However, care should be taken when wiping the patch with a towel because the adhesive borders of the film are very sensitive to any rubbing. The patch is tamper evident in the respect that once applied to the skin, one cannot remove and then reapply the patch because there is no more skin adhesion.
Results of the sweat patch analysis are presented in Table 2 , along with the administered methadone doses. All the patches contain methadone and the ability of the patch was demonstrated to collect and contain the drug. Concentrations ranged from 26 to 1118 ng/patch and 28 to 1114 ng/patch for R-methadone and S-methadone, respectively. Table 2 Although methadone has been identified and quantified previously in sweat (6, (20) (21) (22) this is the first report of enantioselective separation of methadone. Some of these reports have also presented data on the major metabolite, 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP) that was always detected in much lower concentration than the parent drug. In spite of its identification in this study, in concentrations ranging from not detected to 117 ng/patch, no particular attention was given to the metabolite because it has been definitively demonstrated that the main analyte excreted in sweat is the parent drug (23) .
Although the limited number of subjects in this study precludes generalization, results are suggestive of a predominance of the R-enantiomer of methadone in human sweat. The ratio between R-and S-methadone was in the range of 0.72 to 2.66 and was higher than 1.00 in 15 specimens. The pairedt-test (StatView II soft, version 1.02; Macintosh, Brainpower, Calabasas, CA, U.S.A.) applied to the results showed that the difference[R-met-S-met] with a mean value of 81 is significantly different from 0 at a probability p < 8%.
The findings of methadone in sweat is of particular interest to document drug exposure of the subject. Methadone was administered under close medical supervision. Fig. 3 No correlation could be established between daily doses and total R-and S-methadone in sweat because r 2 = 0.014 (Fig.   3) . However, the small dose range of methadone has to be considered in these observations. Substantial intersubject variability seems to be associated with the excretion of methadone in sweat. Same observations were also described with buprenorphine (3) and heroin (9) . Therefore, sweat testing seems to be a qualitative rather than a quantitative test to estimate the amount of drug ingested.
The success of urine drug testing of drug abusers is dependent on the frequency of testing. Most drugs of abuse are detected in urine for 2 to 3 days after a single drug exposure. Therefore, to be effective, two urine tests have to be performed each week. Data from the literature indicated that, in detoxification centers, one sweat patch appears to be as effective as two urine tests performed each week (3, 24) . The test appears to be very sensitive because the administration of low doses of cocaine (~1 to 5 mg) produced detectable amount in sweat (2) . Sweat testing appears to offer the advantage of being a relatively noninvasive means of obtaining a cumulative estimate of drug exposure over a long period (1 week), whereas urine is an incremental measure with some invasiveness.
Methods for evading urinalysis, such as adulteration or intake of large amount of fluids are not able to affect sweat. Specimens can be obtained more easily with less embarassment. However, the cost-per-unit test is different according to the nature of the specimens. Sweat testing is more expensive than urine testing, and generally requires chromatographic procedures in comparison with immunoassay screening. However, this new technology is particularly suitable in rehabilitation centers when it is important for medical personnel to get information on the behavior of the patients. Patches can be worn continuously for at least 10 days and constitute a record of drug intake during that period. It is also possible that the sweat patch had a positive effect on addicts. If the subject realizes that the patch can collect and retain evidence of even a single drug exposure, this understanding may deter drug use (23) .
Finally, the enantioselective determination of methadone in sweat can be used to document models for drug incorporation in hair. The earliest theoretical position was that drugs present in the bloodstream are entrapped in the hair during the growth process and after the hair emerges from the scalp, these drugs form bands that are in direct proportion to the concentrations present when the hair was formed (25). However, controlled studies with cocaine-d 5 (26) indicated that the drug may be detected in hair within hours after administration. Because it takes several days for the hair to emerge from the scalp, other mechanisms for drug incorporation were postulated. We demonstrated that the major enantiomer of methadone in hair was the R-isomer (18) and that these findings appeared contradictory with higher levels of S-methadone in serum, as reported in the literature (13) (14) (15) (16) . For these reasons, sweat was proposed to account for drug incorporation in hair after the hair has emerged from the skin (19) . Our findings on enantioselective composition of sweat supports the idea that drug incorporation in hair is linked to sweat. Moreover, there are substantial difficulties in explaining why parent drugs are found in higher concentrations than metabolites in hair, although in controlled studies, in plasma, the area under the curve of the parent drug is lower than that of the metabolites (27). Again, sweat, with larger amount of parent drug, can be considered as a specimen that influences drug incorporation in hair.
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CONCLUSION
The sweat patch has demonstrated useful application for monitoring drug exposure. Although the quantitative interpretation of the results of perspiration is rather difficult, these analyses may provide a probative value for establishing drug exposure. Moreover, the enantioselective separation of R-and S-methadone can be used to document some physiologic mechanisms of excretion and incorporation. Table 1   Table 2 Fig . 3 
Back to Top
